Literature DB >> 7852520

Abnormal concentration of maternal serum activin-A in gestational diseases.

F Petraglia1, D De Vita, A Gallinelli, L Aguzzoli, A R Genazzani, R Romero, T K Woodruff.   

Abstract

Serum plasma activin-A is measurable in the maternal circulation of healthy pregnant women, increases in specimens collected during the third trimester of gestation, and is highest at parturition. Hormone abnormalities are known to be associated with preterm labor or diabetes in pregnancy. Therefore, in the present study serum activin-A levels in normal controls were compared to those in pregnant women with preterm labor or gestational diabetes. In some cases, values were obtained before and after insulin therapy. In other controls and patients with preterm labor, the activin-A concentration in cord serum was also studied. A newly developed two-site immunotest was used to determine activin-A levels. Subjects included normal controls (n = 7), who were sampled throughout gestation every 5 weeks; pregnant women at term (38-40 weeks) not in labor (n = 22); pregnant women at term in spontaneous labor (< 3.0 cm dilated; n = 42); women in preterm labor (25-35 weeks; n = 38); and women with gestational diabetes (20-39 weeks; n = 9). In control women, serum activin-A levels increased from 4.8 +/- 5.5 micrograms/L (mean +/- SD) at 20 weeks to 25.4 +/- 27.8 micrograms/L at 40 weeks (P < 0.01), and values correlated with gestational age. Pregnant women in preterm labor had serum activin-A concentrations (89.04 +/- 173.31 micrograms/L) higher than those in normal controls (P < 0.01), and no significant correlation to gestational age was found in this group of pregnant women. Healthy women in labor showed serum activin-A concentrations higher than those in women at term but not in labor (P < 0.01). Diabetic patients had serum activin-A concentrations (52.39 +/- 23.32 micrograms/L) significantly higher than those in normal controls. In these patients, maternal serum activin-A concentrations significantly decreased to the range in healthy controls at the same gestational age after insulin therapy (9.48 +/- 3.82 micrograms/L). The present study shows that preterm labor is associated with increased concentrations of activin-A in the maternal circulation and cord serum. Hypersecretion of activin-A is also shown in same patients with gestation diabetes; this reverts to normal after insulin treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7852520     DOI: 10.1210/jcem.80.2.7852520

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

Review 2.  Inhibin at 90: from discovery to clinical application, a historical review.

Authors:  Yogeshwar Makanji; Jie Zhu; Rama Mishra; Chris Holmquist; Winifred P S Wong; Neena B Schwartz; Kelly E Mayo; Teresa K Woodruff
Journal:  Endocr Rev       Date:  2014-07-22       Impact factor: 19.871

3.  Serum levels of dimeric activin A are not a marker of placental tumors in the course of chemotherapy.

Authors:  P Florio; S Luisi; E Casarosa; A R Genazzani; P Pautier; C Lhommé; J M Bidart; P G Driul; F Petraglia
Journal:  J Endocrinol Invest       Date:  1998-03       Impact factor: 4.256

Review 4.  Activins and Inhibins: Roles in Development, Physiology, and Disease.

Authors:  Maria Namwanje; Chester W Brown
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-07-01       Impact factor: 10.005

5.  Activin A stimulates insulin secretion in cultured human pancreatic islets.

Authors:  P Florio; S Luisi; P Marchetti; R Lupi; L Cobellis; C Falaschi; H Sugino; R Navalesi; A R Genazzani; F Petraglia
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

6.  Activin-A in myometrium: characterization of the actions on myometrial cells.

Authors:  Pasquapina Ciarmela; Ezra Wiater; Wylie Vale
Journal:  Endocrinology       Date:  2008-01-31       Impact factor: 4.736

7.  Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia.

Authors:  E Fitzpatrick; M P Johnson; T D Dyer; S Forrest; K Elliott; J Blangero; S P Brennecke; E K Moses
Journal:  Mol Hum Reprod       Date:  2009-01-06       Impact factor: 4.025

8.  Serum activin A and follistatin levels in gestational diabetes and the association of the Activin A-Follistatin system with anthropometric parameters in offspring.

Authors:  Silvia Näf; Xavier Escote; Mónica Ballesteros; Rosa Elena Yañez; Inmaculada Simón-Muela; Pilar Gil; Gerard Albaiges; Joan Vendrell; Ana Megia
Journal:  PLoS One       Date:  2014-04-24       Impact factor: 3.240

9.  First-trimester follistatin-like-3 levels in pregnancies complicated by subsequent gestational diabetes mellitus.

Authors:  Ravi Thadhani; Camille E Powe; May Lee Tjoa; Eliyahu Khankin; Jun Ye; Jeffrey Ecker; Alan Schneyer; S Ananth Karumanchi
Journal:  Diabetes Care       Date:  2009-12-10       Impact factor: 19.112

Review 10.  Melatonin for the Management of Preeclampsia: A Review.

Authors:  Annie Langston-Cox; Sarah A Marshall; Daisy Lu; Kirsten R Palmer; Euan M Wallace
Journal:  Antioxidants (Basel)       Date:  2021-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.